News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK Cost Agency Turns Down New Roche (RHHBY) Breast Cancer Drug


8/6/2013 7:05:25 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Roche's new breast cancer drug Perjeta is not worth using on Britain's state health service given its high price and the lack of data showing how long it might extend life, the country's healthcare cost watchdog said. The National Institute for Health and Clinical Excellence (NICE) said on Tuesday it could not be sure of Perjeta's benefits, adding that not even the manufacturer estimated it would be considered cost-effective for the National Health Service. NICE's draft recommendation against using Perjeta is now open for consultation before final guidance is issued.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
Roche
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES